Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CG5503 PR on QT/QTc Interval in Healthy Volunteers
NCT03951402Phase 1Completed
- Sponsor
- Grünenthal GmbH
- Start
- Mar 2003
- Primary completion
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tapentadol in pain (4 arms), sponsored by Grünenthal GmbH. Primary endpoint: Corrected QT Interval at Day 3. Started Mar 2003; status: completed.
02
Drugs
tapentadol
03
Conditions
pain
Beyond the preview
Go deeper on NCT03951402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951402.